

COPY OF PAPER
ORIGINALLY FILED

S/N 09/785,546

PATENT

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sonya Franklin

Examiner: Charles L. Patterson, Jr., Ph.D.

Serial No.: 09/785,546

Group Art Unit: 1652

Filed: February 16, 2001

Docket: 875.037US1

Title: ARTIFICIAL ENDONUCLEASE

RECEIVED

#15
A.G.
7/29/02

RESPONSE TO NOTICE OF INCOMPLETE RESPONSE

JUL 25 2002

Commissioner for Patents
Washington, D.C. 20231

TECH CENTER 1600/2900

Applicant has reviewed the Office Communication mailed on June 17, 2002. In the Communication, the Examiner indicated that in the Response to the Restriction Requirement mailed May 6, 2002, Applicant elected a group of claims that had not been presented in the Restriction Requirement mailed March 4, 2002. Accordingly, Applicant provisionally elects, with traverse, the claims of Group I (claims 1-2, 4-18, and 27-29), directed to an isolated synthetic peptide or polypeptide comprising a domain which specifically binds a nucleic acid sequence and a domain which specifically binds a metal which is hydrolytic or redox active, wherein the domain which specifically binds the metal is within the domain which specifically binds the nucleic acid sequence, wherein the peptide or polypeptide comprises SEQ ID NO:2. Reconsideration and withdrawal of the restriction requirement, in view of the remarks herein, is respectfully requested.

Applicant respectfully requests the Examiner to consider that Applicant's invention is generally directed to an isolated synthetic peptide or polypeptide comprising a domain which specifically binds a nucleic acid sequence and a domain which specifically binds a metal which is hydrolytic or redox active, wherein the domain which specifically binds the metal is within the domain which specifically binds the nucleic acid sequence (i.e., the peptide or polypeptide is a synthetic endonuclease, claims 1-18 and 30-33), an isolated nucleic acid molecule, expression cassette or vector encoding the peptide or polypeptide of the invention, or host cell comprising the expression cassette of the invention (claims 19-25), methods of using the peptide or polypeptide of the invention (claims 27-29) and a method to identify a synthetic endonuclease (claim 26).

Claims 2-3 and 30-33, which depend on claim 1, each recite an amino acid sequence for a peptide or polypeptide of the invention. In particular, SEQ ID NO:2 (claim 2; assigned to Group

I) includes nucleic acid binding sequences of Engrailed and a consensus EF-Hand loop sequence (a metal binding domain); SEQ ID NO:3 (claim 3; assigned to Group II) includes $\alpha 2$ and $\alpha 3$ of Engrailed minus the last turn of $\alpha 2$ and a β turn and calmodulin loop I (a metal binding domain); SEQ ID NO:4 (claim 30; assigned to Group III) includes $\alpha 2$ and $\alpha 3$ of Engrailed and a greater portion of calmodulin loop I than SEQ ID NO:3; SEQ ID NO:5 (claim 31; assigned to Group IV) includes $\alpha 2$ and $\alpha 3$ of Antennapedia and calmodulin loop III (a metal binding domain); SEQ ID NO:6 (claim 32; assigned to Group V) includes a calmodulin loop I modified Engrailed sequence; and SEQ ID NO:7 (claim 33; SEQ ID NO:7 is similar to SEQ ID NO:2 except that position 24 is W not H). As each amino acid sequence recited in the claims was grouped separately, claim 33 would likely have been assigned to Group VIII along with claims 1, 4-18, and 27-29.

Figure 2 of the specification (a copy was enclosed with the Response to the Restriction Requirement mailed on May 6, 2002), which illustrates metal binding domains by shading, EF-Hand related sequences by a single underline, and nucleic acid binding sequences, e.g., homeodomains, by double underlining, shows the structural similarity of SEQ ID Nos:2-7. For example, all of SEQ ID NOs:2-7 have the motifs: DKDGN/DGT/Y/Fl, TE/RRRR, and W/HFQN, and all but one has the motif: KIW/HFQNKRRARIK. Thus, the peptides of SEQ ID NOs:2-7, and in particular the peptides of SEQ ID NOs:2-5 and 7, are, at the primary amino acid sequence level, related.

Moreover, based on Applicant's disclosure, Applicant's Representatives urge the Examiner to consider the following groups of claims for election in a revised Restriction Requirement: claims 1-18 and 27-33 (group A), directed to a synthetic peptide or polypeptide of the invention and methods of using the synthetic endonuclease; claims 19-25 (group B), directed to an isolated nucleic acid molecule, expression cassette or vector encoding the peptide or polypeptide of the invention, or host cell comprising the expression cassette of the invention; and claim 26 (group C) directed to a method to identify a synthetic endonuclease.

The Restriction Requirement is traversed on the basis that the inventions are so closely related within the context of the disclosure of the application that they cannot properly be considered independent and distinct within the statutory meaning of 35 U.S.C. § 121. In view of

Applicant's disclosure, it is clear that claims directed to an isolated synthetic peptide or polypeptide comprising a domain which specifically binds a nucleic acid sequence and a domain which specifically binds a metal which is hydrolytic or redox active, wherein the domain which specifically binds the metal is within the domain which specifically binds the nucleic acid sequence, wherein the peptide or polypeptide comprises SEQ ID NO:2

(TERRRQQLDKDGDGTIDEREIKIHF QNKRAKIK) and methods of using that peptide or polypeptide (claims 1-2, 4-18, and 27-29; Group I) are related to claims directed to an isolated synthetic peptide or polypeptide comprising a domain which specifically binds a nucleic acid sequence and a domain which specifically binds a metal which is hydrolytic or redox active, wherein the domain which specifically binds the metal is within the domain which specifically binds the nucleic acid sequence, wherein the peptide comprises SEQ ID NO:7

(TERRRQQLDKDGDGTIDEREIKIWFQNKRAKIK) and methods of using that peptide or polypeptide (claims 1, 4-18, 27-29, and 33); claims directed to an isolated synthetic peptide or polypeptide comprising a domain which specifically binds a nucleic acid sequence and a domain which specifically binds a metal which is hydrolytic or redox active, wherein the domain which specifically binds the metal is within the domain which specifically binds the nucleic acid sequence, wherein the peptide comprises SEQ ID NO:3 (TERRRFDKDGNGYISAAELRHV

KIWFQNKRAKIK) and methods of using that peptide or polypeptide (claims 1, 3-18 and 27-29; Group II); claims directed to an isolated synthetic peptide or polypeptide comprising a domain which specifically binds a nucleic acid sequence and a domain which specifically binds a metal which is hydrolytic or redox active, wherein the domain which specifically binds the metal is within the domain which specifically binds the nucleic acid sequence, wherein the peptide comprises SEQ ID NO:4 (TERRRFRVFDKDGNGYISAAEKIW FQNKEAKIK) and methods of

using that peptide or polypeptide (claims 1, 4-18 and 27-30; Group III); claims directed to an isolated synthetic peptide or polypeptide comprising a domain which specifically binds a nucleic acid sequence and a domain which specifically binds a metal which is hydrolytic or redox active, wherein the domain which specifically binds the metal is within the domain which specifically binds the nucleic acid sequence, wherein the peptide comprises SEQ ID NO:5

(TRRRRFSLFDKDGDTITTKEEVWFQNRMMKWK) and methods of using that peptide or

polypeptide (claims 1, 4-18, 27-29, and 31; Group IV); claims directed to an isolated synthetic peptide or polypeptide comprising a domain which specifically binds a nucleic acid sequence and a domain which specifically binds a metal which is hydrolytic or redox active, wherein the domain which specifically binds the metal is within the domain which specifically binds the nucleic acid sequence, wherein the peptide comprises SEQ ID NO:6 (DEKRPRTAFSGEQLARLKREFNENRYLTERRRLRVFDKDGNGFISAAEKIWFQNKRAKIKKST) and methods of using that peptide or polypeptide (claims 1, 4-18, 27-29 and 32; Group V).

The Restriction Requirement is also traversed on the basis that Restriction Requirements are optional in all cases. M.P.E.P. § 803. If the search and examination of an entire application can be made without serious burden, the Examiner must examine it on the merits, even though it arguably may include claims to distinct or independent inventions. M.P.E.P. § 803. Moreover, it is submitted that Applicant should not be required to incur the additional costs associated with the filing of multiple divisional applications in order to obtain protection for the claimed subject matter, e.g., five divisional applications in addition to the present application to obtain protection for six sequences. Due to the relatedness of the subject matter of the claims in Group I and claim 33 and Groups II-V, as discussed above, the claims in Group I, claim 33 and Groups II-V can be efficiently and effectively searched in a single search with no additional burden placed on the Examiner. In particular, the claims in Groups I-V and claim 33 can be efficiently and effectively searched in a single search with no additional burden placed on the Examiner as the claims in Groups I-V and claim 33 (claim 33 is presumably classified in the same class and subclass as claims which recite SEQ ID NO:2, as SEQ ID NO:2 has a single amino acid substitution relative to SEQ ID NO:7) are in the same class and subclass for search purposes.

Moreover, as each of the claims which recite a particular amino acid sequence (claims 2-3 and 30-33) are dependent on (linked to) claim 1, claims 1-18 and 27-33 should be examined in the same application. M.P.E.P. 809.03. Thus, the Restriction Requirement is properly traversed. Accordingly, reconsideration and withdrawal of the Restriction Requirement is respectfully requested.

Further, in the event the Examiner remains of the opinion that the restriction is proper as

stated in the Restriction Requirement dated March 4, 2002, Applicant's Representatives respectfully request that the group elected for prosecution on the merits in the present application is a group which includes claims 1, 4-18, 27-29, and 33, directed to an isolated synthetic peptide or polypeptide comprising a domain which specifically binds a nucleic acid sequence and a domain which specifically binds a metal which is hydrolytic or redox active, wherein the domain which specifically binds the metal is within the domain which specifically binds the nucleic acid sequence, wherein the peptide or polypeptide comprises SEQ ID NO:7 (proposed Group VIII).

Applicant's Representatives also respectfully request rejoinder of Groups I-V with Group VIII if Group VIII is the elected group, or Groups II-V and VIII with Group I if Group I is the elected group, in the present application upon a notice of allowable subject matter for the claims in Group VIII or Group I, respectively.

The Examiner is invited to contact Applicant's attorney (612-373-6959) if there are any questions concerning this Response or if prosecution of this application may be assisted thereby.

RESPONSE TO NOTICE OF INCOMPLETE RESPONSE

Serial Number: 09/785,546

Filing Date: February 16, 2001

Title: ARTIFICIAL ENDONUCLEASE

Page 6

Dkt: 875.037US1

If necessary, please charge any additional fees or credit overpayment to Deposit Account No. 19-0743.

Respectfully submitted,

SONYA FRANKLIN,

By her Representatives,

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.

P.O. Box 2938

Minneapolis, MN 55402

(612) 373-6959

Date

July 17, 2002

By

Janet E. Embretson

Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner of Patents, Washington, D.C. 20231, on this 17 day of July, 2002.

Name

Candis B. Buending

Signature

Candis B. Buending



COPY OF PAPERS
ORIGINALLY FILED

Gp#1652

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant: Sonya Franklin
Title: ARTIFICIAL ENDONUCLEASE
Docket No.: 875.037US1
Filed: February 16, 2001
Examiner: Charles L. Patterson, Jr., Ph.

Serial No.: 09/785,546
Due Date: July 17, 2002
Group Art Unit: 1652

RECEIVED
JUL 25 2002
TECH CENTER 1600/2900

Commissioner for Patents
Washington, D.C. 20231


We are transmitting herewith the following attached items (as indicated with an "X"):

- ☒ A return postcard.
- ☒ Response to Notice of Incomplete Response (6 Pages).

Please consider this a PETITION FOR EXTENSION OF TIME for sufficient number of months to enter these papers and please charge any additional required fees or credit overpayment to Deposit Account No. 19-0743.

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A.
P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)

By:


Atty: Janet E. Embretson
Reg. No. 39,665

CERTIFICATE UNDER 37 CFR 1.8: The undersigned hereby certifies that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail, in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231, on this 17th day of July, 2002.

Candis B Buending

Name

Signature

Customer Number 21186

SCHWEGMAN, LUNDBERG, WOESSNER & KLUTH, P.A. P.O. Box 2938, Minneapolis, MN 55402 (612-373-6900)
(GENERAL)